CELZ Stock Overview
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments.
+ 1 more risk
Creative Medical Technology Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.73|
|52 Week High||US$17.15|
|52 Week Low||US$0.58|
|1 Month Change||-0.57%|
|3 Month Change||-52.56%|
|1 Year Change||-94.35%|
|3 Year Change||-99.19%|
|5 Year Change||-100.00%|
|Change since IPO||-100.00%|
Recent News & Updates
|CELZ||US Biotechs||US Market|
Return vs Industry: CELZ underperformed the US Biotechs industry which returned -22.2% over the past year.
Return vs Market: CELZ underperformed the US Market which returned -8.9% over the past year.
|CELZ Average Weekly Movement||13.5%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: CELZ is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: CELZ's weekly volatility has decreased from 25% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Creative Medical Technology Holdings Fundamentals Summary
|CELZ fundamental statistics|
Is CELZ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CELZ income statement (TTM)|
|Cost of Revenue||US$50.24k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.62|
|Net Profit Margin||-9,342.00%|
How did CELZ perform over the long term?See historical performance and comparison
Is CELZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CELZ?
Other financial metrics that can be useful for relative valuation.
|What is CELZ's n/a Ratio?|
Price to Book Ratio vs Peers
How does CELZ's PB Ratio compare to its peers?
|CELZ PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
BRTX BioRestorative Therapies
ACOR Acorda Therapeutics
TENX Tenax Therapeutics
CELZ Creative Medical Technology Holdings
Price-To-Book vs Peers: CELZ is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (0.6x).
Price to Earnings Ratio vs Industry
How does CELZ's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: CELZ is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (2x)
Price to Book Ratio vs Fair Ratio
What is CELZ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.4x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate CELZ's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CELZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CELZ's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CELZ's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Creative Medical Technology Holdings forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CELZ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CELZ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CELZ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CELZ's revenue (105.3% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: CELZ's revenue (105.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CELZ's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Creative Medical Technology Holdings performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CELZ is currently unprofitable.
Growing Profit Margin: CELZ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CELZ is unprofitable, and losses have increased over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare CELZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CELZ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: CELZ has a negative Return on Equity (-37.6%), as it is currently unprofitable.
Discover strong past performing companies
How is Creative Medical Technology Holdings's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: CELZ's short term assets ($22.9M) exceed its short term liabilities ($389.8K).
Long Term Liabilities: CELZ has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CELZ has more cash than its total debt.
Reducing Debt: CELZ had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CELZ has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CELZ has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 28% each year.
Discover healthy companies
What is Creative Medical Technology Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CELZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CELZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CELZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CELZ's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as CELZ has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Warbington (60 yo)
Mr. Timothy Warbington, also known as Tim, has served as the Director and as Chief Executive Officer of Creative Medical Technology Holdings, Inc. since February 2016 and serves as its President since May...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD98.68K) is below average for companies of similar size in the US market ($USD753.27K).
Compensation vs Earnings: Insufficient data to compare Tim's compensation with company performance.
Experienced Management: CELZ's management team is seasoned and experienced (6.5 years average tenure).
Experienced Board: CELZ's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CELZ insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 473.8%.
Creative Medical Technology Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Creative Medical Technology Holdings, Inc.
- Ticker: CELZ
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$10.212m
- Shares outstanding: 14.07m
- Website: https://www.creativemedicaltechnology.com
Number of Employees
- Creative Medical Technology Holdings, Inc.
- 211 East Osborn Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.